POSITION
Investor
BOARD
None
EXIT
Acquired by Mitsubishi Tanabe Pharma in July 2013
Medicago is a clinical-stage biotechnology company focused on developing highly effective and competitive vaccines and therapeutic proteins based on proprietary manufacturing technologies and Virus-Like Particles (VLP). Medicago’s VLP manufacturing technology is based on a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has the potential to offer speed and cost advantages over competitive technologies. It can deliver a vaccine for testing in less than a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market.
The company was acquired by Mitsubishi Tanabe Pharma in July 2013.